RET and non-small cell lung carcinoma: CNS-penetrant TKIs have demonstrated activity in LM in patients with oncogene-driven NSCLC, including alectinib in ALK fusion-positive [161], selpercatinib in RET-rearranged [162], and osimertinib in EGFR-mutated [163,164].